1. Harris RS, Liddament MT. Retroviral restriction by APOBEC proteins. Nat Rev Immunol 4, 868-877 (2004).
2. Conticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol Biol Evol 22, 367-377 (2005).
3. Chan L. RNA editing: exploring one mode with apolipoprotein B mRNA. Bioessays 15, 33-41 (1993).
4. Teng B, Burant CF, Davidson NO. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 260, 1816-1819 (1993).
5. Navaratnam N, et al. The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. J Biol Chem 268, 20709-20712 (1993).
6. Malim MH. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 364, 675-687 (2009).
7. Feng Y, Baig TT, Love RP, Chelico L. Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front Microbiol 5, 450 (2014).
8. Conticello SG, Langlois MA, Yang Z, Neuberger MS. DNA deamination in immunity: AID in the context of its APOBEC relatives. Adv Immunol 94, 37-73 (2007).
9. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650 (2002).
10. Warren CJ, Van Doorslaer K, Pandey A, Espinosa JM, Pyeon D. Role of the host restriction factor APOBEC3 on papillomavirus evolution. Virus Evol 1, (2015).
11. Warren CJ, et al. APOBEC3A functions as a restriction factor of human papillomavirus. J Virol 89, 688-702 (2015).
12. Burns MB, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366-370 (2013).
13. Alexandrov LB, et al. The repertoire of mutational signatures in human cancer. Nature 578, 94-101 (2020).
14. Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. Cancer Discov 5, 704-712 (2015).
15. Walker BA, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun 6, 6997 (2015).
16. Cescon DW, Haibe-Kains B, Mak TW. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci U S A 112, 2841-2846 (2015).
17. Law EK, et al. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci Adv 2, e1601737 (2016).
18. Starrett GJ, et al. The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis. Nat Commun 7, 12918 (2016).
19. Du Y, Tao X, Wu J, Yu H, Yu Y, Zhao H. APOBEC3B up-regulation independently predicts ovarian cancer prognosis: a cohort study. Cancer Cell Int 18, 78 (2018).
20. Kim YS, Sun S, Yoon JS, Ko YH, Won HS, Kim JS. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer. PLoS One 15, e0230261 (2020).
21. Chen TW, et al. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. Nat Commun 8, 465 (2017).
22. Roper N, et al. APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors. Cell Rep 26, 2651-2666 e2656 (2019).
23. Cannataro VL, et al. APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Oncogene 38, 3475-3487 (2019).
24. Li M, et al. First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem Biol 7, 506-517 (2012).
25. Olson ME, Li M, Harris RS, Harki DA. Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold. ChemMedChem 8, 112-117 (2013).
26. King JJ, et al. Structure-Based Design of First-Generation Small Molecule Inhibitors Targeting the Catalytic Pockets of AID, APOBEC3A, and APOBEC3B. ACS Pharmacol Transl Sci 4, 1390-1407 (2021).
27. Kvach MV, et al. Inhibiting APOBEC3 Activity with Single-Stranded DNA Containing 2'-Deoxyzebularine Analogues. Biochemistry 58, 391-400 (2019).
28. Kvach MV, et al. Differential Inhibition of APOBEC3 DNA-Mutator Isozymes by Fluoro- and Non-Fluoro-Substituted 2'-Deoxyzebularine Embedded in Single-Stranded DNA. Chembiochem 21, 1028-1035 (2020).
29. Kouno T, et al. Crystal structure of APOBEC3A bound to single-stranded DNA reveals structural basis for cytidine deamination and specificity. Nature Communications 8, 15024 (2017).
30. Shi K, et al. Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B. Nat Struct Mol Biol 24, 131-139 (2017).
31. Maiti A, et al. Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA. Nat Commun 9, 2460 (2018).
32. Solomon WC, et al. Mechanism for APOBEC3G catalytic exclusion of RNA and non-substrate DNA. Nucleic Acids Res 47, 7676-7689 (2019).
33. Furukawa A, et al. Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBO J 28, 440-451 (2009).
34. Cohen RM, Wolfenden R. Cytidine deaminase from Escherichia coli. Purification, properties and inhibition by the potential transition state analog 3,4,5,6-tetrahydrouridine. J Biol Chem 246, 7561-7565 (1971).
35. Frick L, Yang C, Marquez VE, Wolfenden R. Binding of pyrimidin-2-one ribonucleoside by cytidine deaminase as the transition-state analogue 3,4-dihydrouridine and the contribution of the 4-hydroxyl group to its binding affinity. Biochemistry 28, 9423-9430 (1989).
36. Betts L, Xiang S, Short SA, Wolfenden R, Carter CW, Jr. Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex. J Mol Biol 235, 635-656 (1994).
37. Carlow DC, Smith AA, Yang CC, Short SA, Wolfenden R. Major contribution of a carboxymethyl group to transition-state stabilization by cytidine deaminase: mutation and rescue. Biochemistry 34, 4220-4224 (1995).
38. Xiang S, Short SA, Wolfenden R, Carter CW, Jr. Transition-state selectivity for a single hydroxyl group during catalysis by cytidine deaminase. Biochemistry 34, 4516-4523 (1995).
39. Carlow DC, Short SA, Wolfenden R. Role of glutamate-104 in generating a transition state analogue inhibitor at the active site of cytidine deaminase. Biochemistry 35, 948-954 (1996).
40. Xiang S, Short SA, Wolfenden R, Carter CW, Jr. The structure of the cytidine deaminase-product complex provides evidence for efficient proton transfer and ground-state destabilization. Biochemistry 36, 4768-4774 (1997).
41. Carlow D, Wolfenden R. Substrate connectivity effects in the transition state for cytidine deaminase. Biochemistry 37, 11873-11878 (1998).
42. Carlow DC, Short SA, Wolfenden R. Complementary truncations of a hydrogen bond to ribose involved in transition-state stabilization by cytidine deaminase. Biochemistry 37, 1199-1203 (1998).
43. Leija C, et al. Pyrimidine Salvage Enzymes Are Essential for De Novo Biosynthesis of Deoxypyrimidine Nucleotides in Trypanosoma brucei. PLoS Pathog 12, e1006010 (2016).
44. Frances A, Cordelier P. The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy? Mol Ther 28, 357-366 (2020).
45. Petljak M, et al. Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis. Cell 176, 1282-1294 e1220 (2019).
46. Buisson R, et al. Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features. Science 364, (2019).
47. Hou S, Lee JM, Myint W, Matsuo H, Kurt Yilmaz N, Schiffer CA. Structural basis of substrate specificity in human cytidine deaminase family APOBEC3s. J Biol Chem 297, 100909 (2021).
48. Johansson E, Mejlhede N, Neuhard J, Larsen S. Crystal structure of the tetrameric cytidine deaminase from Bacillus subtilis at 2.0 A resolution. Biochemistry 41, 2563-2570 (2002).
49. Chung SJ, Fromme JC, Verdine GL. Structure of human cytidine deaminase bound to a potent inhibitor. J Med Chem 48, 658-660 (2005).
50. Teh AH, Kimura M, Yamamoto M, Tanaka N, Yamaguchi I, Kumasaka T. The 1.48 A resolution crystal structure of the homotetrameric cytidine deaminase from mouse. Biochemistry 45, 7825-7833 (2006).
51. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303, 41-44 (1983).
52. Varghese JN, Laver WG, Colman PM. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 303, 35-40 (1983).
53. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14, 327-332 (1992).
54. Kim CU, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119, 681-690 (1997).
55. von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6, 967-974 (2007).
56. Tokuda K, Watanabe C, Okiyama Y, Mochizuki Y, Fukuzawa K, Komeiji Y. Hydration of ligands of influenza virus neuraminidase studied by the fragment molecular orbital method. J Mol Graph Model 69, 144-153 (2016).
57. Roberts NA, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 248, 358-361 (1990).
58. Dorsey BD, et al. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem 37, 3443-3451 (1994).
59. Kempf DJ, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A 92, 2484-2488 (1995).
60. Kaldor SW, et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem 40, 3979-3985 (1997).
61. Sham HL, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 42, 3218-3224 (1998).
62. Turner SR, et al. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 41, 3467-3476 (1998).
63. Robinson BS, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 44, 2093-2099 (2000).
64. Koh Y, et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 47, 3123-3129 (2003).
65. De Meyer S, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 49, 2314-2321 (2005).
66. Surleraux DL, et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem 48, 1813-1822 (2005).
67. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276, 307-326 (1997).
68. Bunkoczi G, Echols N, McCoy AJ, Oeffner RD, Adams PD, Read RJ. Phaser.MRage: automated molecular replacement. Acta Crystallogr D Biol Crystallogr 69, 2276-2286 (2013).
69. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60, 2126-2132 (2004).
70. Murshudov GN, et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 67, 355-367 (2011).
71. Adams PD, et al. The Phenix software for automated determination of macromolecular structures. Methods 55, 94-106 (2011).
72. Chen VB, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66, 12-21 (2010).
73. Labarga A, Valentin F, Anderson M, Lopez R. Web services at the European Bioinformatics Institute. Nucleic Acids Research 35, W6-W11 (2007).
74. Pettersen EF, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 25, 1605-1612 (2004).